Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
SL6-H5255 | Human | Human SLITRK6 Protein, Mouse IgG2a Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
SL6-H5226 | Human | Human SLITRK6 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human SLITRK6, His Tag (Cat. No. SL6-H5226) at 2 μg/mL (100 μL/well) can bind Sirtratumab with a linear range of 0.001-0.5 μg/mL (Routinely tested).
The purity of Human SLITRK6, Mouse IgG2a Fc Tag (Cat. No. SL6-H5255) is more than 90% and the molecular weight of this protein is around 186-227 kDa verified by SEC-MALS.
Immobilized Human SLITRK6, Mouse IgG2a Fc Tag (Cat. No. SL6-H5255) at 2 μg/mL (100 μL/well) can bind Sirtratumab with a linear range of 0.5-31 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
sirtratumab vedotin | AGS-15E; ASG-15ME; AGS15C–SGD-1006; Ha15-10ac.1vcMMAE; Ha15-10ac12vcMMAE | Phase 1 Clinical | Agensys, Seattle Genetics | Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Urogenital Neoplasms | Details |
This web search service is supported by Google Inc.